allogeneic anti-CD6 CAR T-regulatory cells

A preparation of allogeneic T-regulatory cells (Tregs) that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the T-cell differentiation antigen CD6, with potential immunmodulating activity. Upon administration, the allogeneic anti-CD6 CAR Tregs may promote immunologic homeostasis and prevent autoimmunity. This may induce tolerance to allogeneic hematopoietic stem cell transplants, prevent graft-versus-host disease (GvHD), and suppress autoimmune pathology. The allogeneic anti-CD6 CAR Tregs also targets and binds to CD6, which may prevent CD6-mediated activation pathways, downregulate the activation and differentiation of T cells, and reduce the synthesis of pro-inflammatory cytokines. CD6, a co-stimulatory molecule predominantly expressed on lymphocytes, is involved in the adhesion and maturation of T cells.